

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jul 2026

### Effect of Neoadjuvant Chemoradiotherapy on Downstaging of Locally Advanced Cancer of Cardia and patient's survival

#### Protocol summary

##### Study aim

Due to the novelty of using neoadjuvant chemoradiotherapy in advanced localized cardia tumor to reduce the stage of the disease and the few studies that have been done in this field, this study designed to investigate the effect of neoadjuvant chemoradiotherapy in reducing the disease stage of cardia tumor. Evaluation of the outcomes performed before and after the intervention.

##### Design

This study is a single arm clinical trial that will be performed on 60 patients. The outcome will be assessed before and after the intervention and evaluated by the blinded assessment team.

##### Settings and conduct

This clinical trial will be performed in Imam Reza AS Hospital in Tabriz on the patients with a diagnosis of cardia cancer and tumor staging will be done. After the intervention, the effect of chemoradiotherapy on reducing the stage of tumor will be evaluated. Blinding will be performed for researchers assessing the stage of the disease before and after the intervention.

##### Participants/Inclusion and exclusion criteria

All patients with a diagnosis of cardia with Inclusion criteria: Patients aged 80-18 years Confirmation of advanced localized cardiac adenocarcinoma Not receiving previous chemotherapy and radiotherapy Suitable kidney, liver and bone marrow function Performance status less than equal 2 Non-inclusion criteria: Distant metastasis Patient dissatisfaction with neoadjuvant mototherapy Peritoneal carcinoma

##### Intervention groups

Chemotherapy regimen used in FC patients (5-fluorouracil 800 mg/m<sup>2</sup> intravenously, continuous intravenous infusion for 24 hours daily on days 1 to 5 and cisplatin 15 mg/m<sup>2</sup> intravenously, daily injection on days 1 to 5 for two courses It will be every 21 days. The patients will be treated for 25 sessions of 45Gy radiotherapy for 2 minutes, high energy - 18 mV.

#### Main outcome variables

The tumor staging before and after chemoradiotherapy.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20140203016473N12**

Registration date: **2021-02-07, 1399/11/19**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-02-07, 1399/11/19**

Update count: **0**

##### Registration date

2021-02-07, 1399/11/19

##### Registrant information

##### Name

Farzad Kakaie

##### Name of organization / entity

Tabriz University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 1334 1317

##### Email address

fkakaie@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-04-20, 1399/02/01

##### Expected recruitment end date

2021-04-21, 1400/02/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
Effect of Neoadjuvant Chemoradiotherapy on Downstaging of Locally Advanced Cancer of Cardia and patient's survival

**Public title**  
Effect of chemoradiotherapy on locally advanced cancer of Cardia

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Patients aged between 18 to 80 years old Confirmed advanced localized cardiac adenocarcinoma (stage T3, T4, T2 with lymph node involvement) No history of previous chemotherapy and radiotherapy Proper function of the kidney (serum creatinine  $\leq$  1.5 mg / dl) Proper function of the liver (serum bilirubin  $\leq$  1.5 mg / dl) Proper function of the bone marrow (neutrophil count  $>$  1500 per microliter, platelet count  $>$  100 thousand and Hb  $>$  10) Performance Status  $\leq$  2  
**Exclusion criteria:**  
Distant metastasis Patient dissatisfaction with neoadjuvant therapy Stages T1 and T2 without lymph node involvement (according to the AJCC staging system) Peritoneal carcinoma

**Age**  
From **18 years** old to **80 years** old

**Gender**  
Both

**Phase**  
2-3

**Groups that have been masked**

- Outcome assessor

**Sample size**  
Target sample size: **60**

**Randomization (investigator's opinion)**  
N/A

**Randomization description**

**Blinding (investigator's opinion)**  
Single blinded

**Blinding description**  
The outcome assessor who is responsible for assessing the stage of the disease before and after the intervention (using the results of radiological reports) will be blinded to whether the intervention was performed on patients (before or after the intervention).

**Placebo**  
Not used

**Assignment**  
Single

**Other design features**  
In this study, all patients with cardiac cancer diagnosis will be examined for the stage of tumor before and after receiving chemoradiotherapy .

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

##### Street address

Imam Reza (AS) Hospital, Golgasht Ave.

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5158646978

#### Approval date

2020-09-14, 1399/06/24

#### Ethics committee reference number

IR.TBZMED.REC.1399.620

## Health conditions studied

### 1

#### Description of health condition studied

Cardia cancer

#### ICD-10 code

C16.0

#### ICD-10 code description

Malignant neoplasm of cardia

## Primary outcomes

### 1

#### Description

The stage of cardiac cancer after chemoradiotherapy intervention

#### Timepoint

4 to 6 weeks after the intervention

#### Method of measurement

Staging of heads based on Tumor, Node, Metastases (TNM) system

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Patients on FC diet containing 5-fluorouracil 800 mg / m<sup>2</sup> intravenously (Alhavi Pharmaceutical Co.), continuous intravenous infusion for 24 hours daily on days 1 to 5 and cisplatin 15 mg / m<sup>2</sup>

intravenously (Sobhan Oncology Pharmaceutical Co.), daily injection on days 1 to 5 for two periods Every 21 days with 25 sessions of 45Gy radiotherapy for 2 minutes, high energy - 18 mV

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Imam Reza Hospital, Tabriz University of Medical Sciences

**Full name of responsible person**

Farzad Kakai

**Street address**

Golgasht Ave.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5158646978

**Phone**

+98 41 3337 8093

**Email**

fkakaei@yahoo.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hassan Soleiman Pour

**Street address**

Golgasht Ave.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5158646978

**Phone**

+98 41 3335 7310

**Email**

Research-vice@tbzmed.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Farzad Kakai

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

General Surgery

**Street address**

Golgasht Ave.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5158646978

**Phone**

+98 41 3337 8093

**Email**

fkakaei@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Farzad Kakai

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

General Surgery

**Street address**

Golgasht Ave.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5158646978

**Phone**

+98 41 3337 8093

**Email**

fkakaei@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Araz Moin

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

General Surgery

**Street address**

Golgasht Ave.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5158646978

**Phone**

+98 41 3337 8093

**Email**

araz.moin1985@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available